AI Drug Discovery Is Not One Thing
AI drug discovery is not one breakthrough. It is a stack of tools for target discovery, molecule design, toxicity prediction, clinical trials, and repurposing — each with a different burden…
AI Drug Discovery Is Getting Its Market Map
The AI drug discovery market is projected to grow from $8.8 billion in 2026 to $114.4 billion by 2033. The bigger story is whether AI can turn better maps of…
The First Wave of AI-Designed Drugs Hits Human Trials: A 2026 Status Report on Insilico, Isomorphic, and Recursion
As of May 2026, more than 75 AI-discovered drugs are in human trials. Inside the Insilico IPF Phase 2 program, Isomorphic Labs partnerships with Novartis and Lilly, Recursion’s Phase 2…
The Relative Risk Trick
How a single statistical framing turns small absolute effects into headlines, billion dollar markets, and confident clinical advice.
Prospective vs Retrospective
The quiet difference between two kinds of validation studies decides whether a healthcare AI product will work in the world. Most published claims live on the wrong side of it.
How to Read a Healthcare AI Press Release
The healthcare AI press release is often the version of a claim most people ever encounter. This field guide shows how to read one in under ten minutes, using eight…
The Resolution Gap
Most healthcare AI claims rest on a data layer that is, by the standards of the biology it is meant to describe, decades out of date. The fix is the…
Surrogate Endpoints and the Long Wait for Truth
A measurable proxy for a clinical outcome is a useful tool, until the field forgets that the proxy is not the outcome. Healthcare AI and longevity science have not yet…
The Reproducibility Crisis Healthcare AI Refuses to Talk About
A growing body of evidence suggests that a meaningful share of healthcare AI’s published claims would not survive independent reproduction. The field has not yet decided to confront this.
After the Bitter Lesson
How healthcare AI actually gets built in the foundation model era.
